Westphal variant huntington disease and refractory catatonia: A case report

Cognitive and Behavioral Neurology

Volumn 24, Issue 4, 2011, Pages 204-208

  Merida Puga, Jorge ^a   Ramirez Bermudez, Jesus ^a,c   Aguilar Venegas, Luis Carlos ^a   Fricchione, Gregory L ^d   Espinola Nadurille, Mariana ^a,b  

^a Departments of Neuropsychiatry   (Mexico)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

amantadine; Huntington disease; levodopa; resistant catatonia; Westphal variant

Indexed keywords

AMANTADINE; BENZODIAZEPINE; LEVODOPA; NEUROTRANSMITTER; RISPERIDONE;

ADULT; AGGRESSION; AGGRESSIVENESS; ARTICLE; BEHAVIOR CHANGE; CASE REPORT; CATATONIA; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; HUNTINGTON CHOREA; IRRITABILITY; NIGRONEOSTRIATAL SYSTEM; PERIODIC PARALYSIS; PRIORITY JOURNAL; PSYCHOSIS; REGULATORY MECHANISM;

ADULT; AMANTADINE; CARBIDOPA; CATATONIA; COMBINED MODALITY THERAPY; DOPAMINE AGENTS; DRUG COMBINATIONS; DRUG RESISTANCE; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; HUNTINGTON DISEASE; LEVODOPA;

EID: 83655190780     PISSN: 15433633     EISSN: 15370887     Source Type: Journal    
DOI: 10.1097/WNN.0b013e318240080d     Document Type: Article

References (26)

1. Ross CA, Tabrizi SJ. Huntingtons disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83-98. Review.
2. Low PA, Allsop JL, Halmagyi GM. Huntingtons chorea: the rigid form (Westphal variant) treated with levodopa. Med J Aust. 1974;1:393-394.
3. Alonso ME, Nieto D. Clinical and genetic aspects of Huntingtons disease. Study of 28 patients. Rev Invest Clin. 1985;37:125-130.
4. Mendez MF. Huntingtons disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med. 1994;24:189-208.
5. Paulsen JS, Hoth KF, Nehl C, et al. Critical periods of suicide risk in Huntingtons disease. Am J Psychiatry. 2005;162:725-731. (Pubitemid 40489135)
6. Burns A, Folstein S, Brandt J, et al. Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease. J Nerv Ment Dis. 1990;178:20-26. (Pubitemid 20175040)
7. Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntingtons disease. J Neurol Neurosurg Psychiatry. 2001;71:310-314.
8. Gaasbeek D, Naarding P, Stor T, et al. Drug-induced hyperthermia in Huntingtons disease. J Neurol. 2004;251:454-457.
9. Fink M, Taylor MA. Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1182-1183. (Pubitemid 43928221)
10. Bush G, Kink M, Petrides G, et al. Catatonia: I. Rating Scale and standardized examination. Acta Psychiatr Scand. 1991;93:129-136. (Pubitemid 26084530)
11. Petrides G, Braga R, Fink M, et al. Seizure threshold in a large sample: implications for stimulus dosing strategies in bilateral ECT. A report from CORE. J ECT. 2009;25:232-237.
12. Francis A. Catatonia: diagnosis, classification, and treatment. Curr Psych Rep. 2010;12:180-185.
13. Espinola-Nadurille M, Ramirez-Bermudez J, Fricchione GL. Pregnancy and malignant catatonia. Gen Hosp Psychiatry. 2007;29:69-71. (Pubitemid 44960479)
14. Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntingtons disease. J Neurol Neurosurg Psychiatry. 1998;65:577-579. (Pubitemid 28438897)
15. Bush G, Fink M, Petrides G, et al. Catatonia II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand. 1996;93:137-143. (Pubitemid 26084531)
16. Fink M. The intimate relationship between catatonia and convulsive therapy. J ECT. 2010;26:243-245.
17. Lewis CF, DeQuardo JR, Tandon R. ECT in genetically confirmed Huntingtons disease. J Neuropsychiatry Clin Neurosci. 1996;8:209-210. (Pubitemid 26138930)
18. Beale MD, Kellner CH, Gurecki P, et al. ECT for the treatment of Huntingtons disease: a case study. Convuls Ther. 1997;13:108-112. (Pubitemid 27329397)
19. Ranen NG, Peyser CE, Folstein SE. ECT as a treatment for depression in Huntingtons disease. J Neuropsychiatry Clin Neurosci. 1994;6:154-159. (Pubitemid 24143944)
20. Zwil AS, Pelchat RJ. ECT in the treatment of patients with neurological and somatic disease. Int J Psychiatry Med. 1994;24:1-29. Review. (Pubitemid 24182833)
21. Daniels J. Catatonia: clinical aspects and neurobiological correlates. J Neuropshychiatry Clin Neurosci. 2009;21:371-380.
22. Markham-Abedi C, McNeely C, de Leon J. A case report with ziprasidone-induced catatonic symptoms. J Neuropsychiatry Clin Neurosci. 2007;19:476-477. (Pubitemid 350156115)
23. Carroll BT, Goforth HW, Thomas CH, et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropshychiatry Clin Neurosci. 2007;19: 406-412. (Pubitemid 350156098)
24. Northoff G. What catatonia can tell us about "top-down modulation": a neuropsychiatric hypothesis. Behav Brain Sci. 2002; 25:555-604.
25. Neppe VM. Management of catatonic stupor with L-dopa. Clin Neuropharmacol. 1988;11:90-91. (Pubitemid 18039439)
26. Ali S, Welch CA, Park LT, et al. Encephalitis and catatonia treated with ECT. Cogn Behav Neurol. 2008;21:46-51. (Pubitemid 351355043)